Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A pilot, open-label, rater-blinded, randomized, parallel-group, multi-center study to evaluate the safety, tolerability and preliminary efficacy of three add-on fixed doses of evenamide in patients with treatment-resistant schizophrenia (TRS) not responding adequately to their stable, therapeutically active dose of a single antipsychotic medication.

Next Previous
Trial Profile

A pilot, open-label, rater-blinded, randomized, parallel-group, multi-center study to evaluate the safety, tolerability and preliminary efficacy of three add-on fixed doses of evenamide in patients with treatment-resistant schizophrenia (TRS) not responding adequately to their stable, therapeutically active dose of a single antipsychotic medication.

Status: Active, no longer recruiting
Phase of Trial: Phase II

Latest Information Update: 09 Apr 2024

Price :
$35 *
Note:
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Evenamide (Primary)
  • Indications Schizophrenia
  • Focus Adverse reactions
  • Sponsors Newron Pharmaceuticals

Most Recent Events

  • 08 Apr 2024 According to a Newron Pharmaceuticals media release, data from this study were presented at the 2024 Annual Congress of the Schizophrenia International Research Society (SIRS) from 3-7 April in Florence, Italy.
  • 04 Jan 2024 Final 1-year results presented in a Newron Pharmaceuticals Media Release.
  • 09 Oct 2023 According to a Newron Pharmaceuticals media release, data from this trial were presented at the 36th European Clinical Neuropsychopharmacology Congress (ECNP) in Barcelona, Spain.

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top